{"transactions":[{"id":900257,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2026-02-17T11:06:09.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":33490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":33490,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":33490},"source":{"system":"sec-edgar","filing":"0001193125-26-053610","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526053610/ownership.xml","form_type":"4"}},{"id":949721,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2026-01-05T15:18:06.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":24952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":24952},"source":{"system":"sec-edgar","filing":"0001193125-26-002254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526002254/ownership.xml","form_type":"4"}},{"id":949720,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2026-01-05T15:18:06.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":24952,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52527,"source":{"system":"sec-edgar","filing":"0001193125-26-002254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526002254/ownership.xml","form_type":"4"}},{"id":949719,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2026-01-05T15:18:06.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":19301,"price":16.03,"value":309395.03,"ownership":{"direct":true},"balance_after":33226,"source":{"system":"sec-edgar","filing":"0001193125-26-002254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526002254/ownership.xml","form_type":"4"}},{"id":1269194,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2025-02-13T16:42:58.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":32912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award).\nThe number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half\nif absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at\nthe end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":32912,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":32912},"source":{"system":"sec-edgar","filing":"0000950170-25-019968","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017025019968/ownership.xml","form_type":"4"}},{"id":1313108,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2025-01-03T16:57:53.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":9604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022.  The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022.  The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9604},"source":{"system":"sec-edgar","filing":"0000950170-25-001314","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017025001314/ownership.xml","form_type":"4"}},{"id":1313107,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2025-01-03T16:57:53.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":9604,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33564,"source":{"system":"sec-edgar","filing":"0000950170-25-001314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017025001314/ownership.xml","form_type":"4"}},{"id":1313106,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2025-01-03T16:57:53.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":5989,"price":17.31,"value":103669.59,"ownership":{"direct":true},"balance_after":27575,"source":{"system":"sec-edgar","filing":"0000950170-25-001314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017025001314/ownership.xml","form_type":"4"}},{"id":1640439,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2024-02-15T16:09:32.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":38002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period\nas follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award).\nThe number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period\nas follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award).\nThe number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":38002,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":38002},"source":{"system":"sec-edgar","filing":"0000950170-24-015879","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024015879/ownership.xml","form_type":"4"}},{"id":1683538,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2024-01-08T14:47:14.000Z","date":"2022-12-31","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"The original Form 4, filed on January 4, 2023, is being amended by this Form 4 amendment solely to correct an administrative error in transaction codes used by the issuer, which misreported that 12,000 shares of Common Stock were Disposed of (D) when in fact such shares were Acquired (A) upon vesting of restricted performance shares on December 31, 2022, and subsequently, 4,722 shares of Common Stock were Acquired (A) when in fact such shares were Disposed of (D) to satisfy tax withholding obligations incident to such vesting. The number of shares beneficially owned by the reporting person remains the same after correcting for the error in transaction codes."}],"balance_after":19783,"source":{"system":"sec-edgar","filing":"0000950170-24-002886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024002886/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-04"}},{"id":1683537,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2024-01-08T14:47:14.000Z","date":"2022-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4722,"price":20.27,"value":95714.94,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"The original Form 4, filed on January 4, 2023, is being amended by this Form 4 amendment solely to correct an administrative error in transaction codes used by the issuer, which misreported that 12,000 shares of Common Stock were Disposed of (D) when in fact such shares were Acquired (A) upon vesting of restricted performance shares on December 31, 2022, and subsequently, 4,722 shares of Common Stock were Acquired (A) when in fact such shares were Disposed of (D) to satisfy tax withholding obligations incident to such vesting. The number of shares beneficially owned by the reporting person remains the same after correcting for the error in transaction codes."}],"balance_after":15061,"source":{"system":"sec-edgar","filing":"0000950170-24-002886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024002886/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-04"}},{"id":1683536,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2024-01-08T14:47:14.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":5775,"price":17.66,"value":101986.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4, filed on January 3, 2024, is being amended by this Form 4 amendment to correct an administrative error of the issuer, whereupon the number of shares withheld to satisfy tax withholding obligations upon vesting of certain restricted performance shares was misreported as 5,643 shares.  The corrected transaction reflects an increase of 132 shares withheld by the issuer as a result such vesting and a corresponding reduction in the number of shares beneficially owned by the reporting person."}],"balance_after":23960,"source":{"system":"sec-edgar","filing":"0000950170-24-002886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024002886/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-04"}},{"id":1690479,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2024-01-03T17:46:12.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":14674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021.  The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023.  Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half.  Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021.  The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023.  Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half.  Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":14674},"source":{"system":"sec-edgar","filing":"0000950170-24-001244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024001244/ownership.xml","form_type":"4"}},{"id":1690478,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2024-01-03T17:46:12.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":14674,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29735,"source":{"system":"sec-edgar","filing":"0000950170-24-001244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024001244/ownership.xml","form_type":"4"}},{"id":1690477,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2024-01-03T17:46:12.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":5643,"price":17.66,"value":99655.38,"ownership":{"direct":true},"balance_after":24092,"source":{"system":"sec-edgar","filing":"0000950170-24-001244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000095017024001244/ownership.xml","form_type":"4"}},{"id":2004647,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2023-02-21T15:18:25.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":21418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":21418,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":21418},"source":{"system":"sec-edgar","filing":"0001209191-23-011097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919123011097/doc4.xml","form_type":"4"}},{"id":2069774,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2023-01-04T17:02:44.000Z","date":"2022-12-31","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2020, subject to a three-year performance period that began on January 1, 2020 and ended on December 31, 2022.   All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2020, subject to a three-year performance period that began on January 1, 2020 and ended on December 31, 2022.   All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-23-001063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919123001063/doc4.xml","form_type":"4"}},{"id":2069773,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Shares","published_at":"2023-01-04T17:02:44.000Z","date":"2022-12-31","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19783,"source":{"system":"sec-edgar","filing":"0001209191-23-001063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919123001063/doc4.xml","form_type":"4"}},{"id":2069772,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Shares","published_at":"2023-01-04T17:02:44.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":true,"shares":4722,"price":20.27,"value":95714.94,"ownership":{"direct":true},"balance_after":15061,"source":{"system":"sec-edgar","filing":"0001209191-23-001063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919123001063/doc4.xml","form_type":"4"}},{"id":2389566,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Schreffler Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2022-02-17T17:09:56.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":17588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause, termination by the employee for \"good reason\" (as defined in the employee's employment agreement), or retirement by the employee upon having reached 62 years of age.  The shares would vest, if at all, at the end of the Performance Period as follows: (i) 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (\"BPG\"); (ii) 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG; or (iii) 150% of the award will vest if the Company is the top performing ROIC company of the BPG, all as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Share Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause, termination by the employee for \"good reason\" (as defined in the employee's employment agreement), or retirement by the employee upon having reached 62 years of age.  The shares would vest, if at all, at the end of the Performance Period as follows: (i) 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (\"BPG\"); (ii) 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG; or (iii) 150% of the award will vest if the Company is the top performing ROIC company of the BPG, all as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Share Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":17588,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":17588},"source":{"system":"sec-edgar","filing":"0001209191-22-010869","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919122010869/doc4.xml","form_type":"4"}},{"id":2451229,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Schreffler Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2022-01-04T17:53:15.000Z","date":"2021-12-31","kind":"exercise","acquired":false,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These awards vested at the end of a three-year performance period that began on January 1, 2019 and ended December 31, 2021 (the \"Performance Period\"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's  peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These awards vested at the end of a three-year performance period that began on January 1, 2019 and ended December 31, 2021 (the \"Performance Period\"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's  peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":4700},"source":{"system":"sec-edgar","filing":"0001209191-22-001062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919122001062/doc4.xml","form_type":"4"}},{"id":2451228,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Schreffler Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Shares","published_at":"2022-01-04T17:53:15.000Z","date":"2021-12-31","kind":"exercise","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9633,"source":{"system":"sec-edgar","filing":"0001209191-22-001062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919122001062/doc4.xml","form_type":"4"}},{"id":2451227,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Schreffler Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Shares","published_at":"2022-01-04T17:53:15.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":1850,"price":22.31,"value":41273.5,"ownership":{"direct":true},"balance_after":7783,"source":{"system":"sec-edgar","filing":"0001209191-22-001062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919122001062/doc4.xml","form_type":"4"}},{"id":2662005,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Schreffler Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Shares","published_at":"2021-06-21T16:47:36.000Z","date":"2021-06-18","kind":"other","acquired":false,"shares":2896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Schreffler transferred 2,896 shares to her former spouse pursuant to a Mediated Settlement Agreement implemented by the broker on June 18, 2021. Ms. Schreffler now owns 4,933 shares."}],"balance_after":4933,"source":{"system":"sec-edgar","filing":"0001209191-21-042073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919121042073/doc4.xml","form_type":"4"}},{"id":2840660,"issuer":{"id":11862,"kind":"organization","name":"CORE LABORATORIES N V","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Schreffler Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2021-02-23T16:46:16.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":13810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG all as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG all as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":13810,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":13810},"source":{"system":"sec-edgar","filing":"0001209191-21-013245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000229/000120919121013245/doc4.xml","form_type":"4"}}]}